share_log

ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data From Phase 2 RMCL-002 Clinical Trial on May 28, 2024

ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data From Phase 2 RMCL-002 Clinical Trial on May 28, 2024

ProKidney 將於 2024 年 5 月 28 日舉辦虛擬意見領袖活動,討論糖尿病引起的慢性腎臟病的當前治療前景以及 RMCL-002 二期臨床試驗的數據
GlobeNewswire ·  05/21 19:00

WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe CKD caused by diabetes as well as the importance of preserving kidney function in this patient population. To register, click here.

北卡羅來納州溫斯頓·塞勒姆,2024年5月21日(GLOBE NEWSWIRE)——專注於慢性腎臟病(CKD)的領先臨床晚期細胞治療公司ProKidney Corp.(納斯達克股票代碼:PROK)(“ProKidney” 或 “公司”)將於美國東部時間2024年5月28日星期二上午8點舉辦虛擬KOL活動,由醫學博士(Icahn School)主持 Steven G. Coca,DO,MS(Icahn School)西奈山醫學博士)和阿諾德·席爾瓦醫學博士(亞利桑那大學),他們將討論糖尿病引起的中度至重度 CKD 患者未得到滿足的醫療需求和目前的治療前景,以及在這些患者群體中保持腎功能的重要性。要註冊, 點擊這裏

The event will also focus on the final data presented at the European Renal Association (ERA) Congress on May 25, 2024 from the RMCL-002 Phase 2 trial of ProKidney's lead product candidate, rilparencel (also known as REACT), a first-of-its-kind, patented, proprietary autologous cellular therapy.

該活動還將重點關注2024年5月25日在歐洲腎臟協會(ERA)大會上公佈的最終數據,這些數據來自ProKidney的主要候選產品rilparencel(也稱爲 REACT)的 RMCL-002 二期試驗),這是同類首款獲得專利的專有自體細胞療法。

A live question and answer session will follow the formal presentations.

正式演講之後將舉行現場問答環節。

About Steven G. Coca, DO, MS
Steven G. Coca, DO, MS is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, the Associate Chair for Clinical and Translational Research for the Department of Internal Medicine, and the Director of Clinical Research for the Division of Nephrology. Dr. Coca's research focuses on the utility of blood and urine biomarkers for risk stratification of patients with acute kidney injury and chronic kidney disease. He has been a part of several large NIH funded consortia on biomarkers in kidney disease, including TRIBE-AKI, ASSESS-AKI, CKD Biocon, and the KPMP (Kidney Precision Medicine Project). He has over 300 publications, and has received several awards, including the Distinguished Researcher Award from the American Society of Nephrology in 2021. His work on prognostic biomarkers and risk models has led to the development of KidneyIntelX, a new bioprognostic test for patients with type 2 diabetes and CKD, that was recently approved by the FDA and is commercially in use in clinical practice at several large healthcare systems.

關於 Steven G. Coca、DO、MS
Steven G. Coca,博士,碩士是西奈山伊坎醫學院的醫學教授、內科系臨床和轉化研究副主任以及腎臟病學部臨床研究主任。Coca博士的研究重點是血液和尿液生物標誌物對急性腎損傷和慢性腎臟病患者進行風險分層的用途。他曾是美國國立衛生研究院資助的多個大型腎臟疾病生物標誌物聯盟的一員,包括TRIBE-AKI、ASSESS-AKI、CKD Biocon和KPMP(腎臟精準醫學項目)。他發表了300多篇出版物,並獲得了多個獎項,包括2021年美國腎臟病學會頒發的傑出研究人員獎。他在預後生物標誌物和風險模型方面的研究促成了KidneyIntelX的開發,這是一種針對2型糖尿病和慢性肺病患者的新生物預後測試,最近獲得美國食品藥品管理局的批准,並在多個大型醫療系統的臨床實踐中投入商業使用。

About Arnold L. Silva, MD, PhD
Arnold L. Silva, MD, PhD is the director of the Home Hemodialysis and Peritoneal Dialysis programs at Boise Kidney & Hypertension Institute. Dr. Silva received his bachelor's and master's degrees in Biology from California State University in Fresno, CA. He received his PhD from the University of Arizona in Tucson, studying the physiology of membrane transport and cell volume regulation. He received his MD from the University of Arizona, followed with residency training in internal medicine and nephrology fellowship at the University of Arizona affiliated hospitals. Dr. Silva has been appointed Clinical Assistant Professor of Medicine at the University of Arizona, and has taught in many areas of biology, biochemistry, and physiology for California State University and University of California. Dr. Silva has been very active as an independent investigator in the basic sciences and clinical research throughout his career, and currently acts as a Principal Investigator on projects for Boise Kidney.

關於阿諾德·席爾瓦,醫學博士,博士
Arnold L. Silva,醫學博士,博伊西腎臟與高血壓研究所家庭血液透析和腹膜透析項目主任。席爾瓦博士在加利福尼亞州弗雷斯諾的加利福尼亞州立大學獲得生物學學士和碩士學位。他在亞利桑那大學圖森分校獲得博士學位,研究膜轉運和細胞容量調節的生理學。他在亞利桑那大學獲得醫學博士學位,隨後在亞利桑那大學附屬醫院接受了內科住院醫師培訓和腎臟病學獎學金。席爾瓦博士被任命爲亞利桑那大學醫學臨床助理教授,並曾在加利福尼亞州立大學和加利福尼亞大學的生物學、生物化學和生理學的許多領域任教。席爾瓦博士在其職業生涯中一直是基礎科學和臨床研究的獨立研究員,目前擔任博伊西腎臟項目的首席研究員。

About ProKidney
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program that launched in January 2022. For more information, please visit .

關於 ProKidney
ProKidney是通過細胞療法創新治療慢性腎病的先驅,經過十年的研究,於2015年成立。ProKidney 的主要候選產品 rilparencel(也稱爲 REACT)),是首款獲得專利的專有自體細胞療法,正在評估是否有可能保護腎衰竭風險高的糖尿病患者的腎臟功能。Rilparencel已獲得再生醫學高級療法(RMAT)稱號以及美國食品藥品管理局和歐洲藥品管理局的指導,以支持其正在進行的於2022年1月啓動的3期臨床計劃。欲了解更多信息,請訪問。

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to financial results and expected cash runway, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company's products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company's products, if approved, the advancement of the Company's development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to related to the Company's product candidates, and the advancement and funding of the Company's developmental programs generally. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A ordinary shares on the Nasdaq; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company's products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; the Company's intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company's business; and other risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

前瞻性陳述
本新聞稿包括1995年《私人證券訴訟改革法》中 “安全港” 條款所指的 “前瞻性陳述”。ProKidney的實際業績可能與其預期、估計和預測有所不同,因此,您不應依賴這些前瞻性陳述作爲對未來事件的預測。諸如 “期望”、“估計”、“項目”、“預算”、“預測”、“打算”、“計劃”、“可能”、“將”、“可能”、“應該”、“相信”、“預測”、“潛力”、“繼續” 等詞語以及類似表達(或此類詞語或表達的負面版本)旨在識別此類前瞻性陳述。這些前瞻性陳述包括但不限於公司對財務業績和預期現金流的預期、未來業績、產品開發和商業化(如果獲得批准)、公司產品的潛在收益和影響(如果獲得批准)、潛在的監管批准、公司產品當前或未來市場的規模和潛在增長(如果獲得批准)、公司開發計劃進入和通過臨床的進展以及報告數據的預期時機,提交監管文件或實現與公司候選產品相關的其他里程碑,以及公司發展計劃的總體進展和資金籌措。這些因素大多不在公司的控制範圍內,難以預測。可能導致這種差異的因素包括但不限於:無法維持公司A類普通股在納斯達克的上市;無法實施業務計劃、預測和其他預期,也無法確定和實現更多機會,這些機會可能會受到競爭以及公司盈利增長和管理增長以及留住關鍵員工的能力等因素的影響;在競爭激烈的市場中,經濟衰退的風險和監管格局不斷變化的影響生物技術行業;公司將來無法籌集資金;公司無法獲得和維持其產品的監管許可或批准,以及對任何已批准或批准的產品的任何相關限制和限制;公司無法識別、許可或收購其他技術;公司無法與目前在生物製劑市場和腎臟疾病治療領域營銷或從事其他公司競爭;該市場的規模和增長潛力公司的產品,如果獲得批准,以及其單獨或與其他市場合作爲這些市場提供服務的能力;公司對支出、未來收入、資本要求和額外融資需求的估計;公司的財務業績;公司的知識產權;細胞療法研發固有的不確定性,包括啓動和完成臨床研究的實際時間以及監管機構決策的時間和內容;我們臨床項目的中期結果可能不是預示未來的業績;地緣政治衝突對公司業務的影響;以及公司最新的10-K表年度報告、隨後的10-Q表季度報告以及向美國證券交易委員會提交的其他文件中 “風險因素” 標題下包含的其他風險和不確定性。該公司提醒讀者,上述因素清單並非排他性,並提醒讀者不要過分依賴任何前瞻性陳述,這些陳述僅代表截至發佈之日。公司不承擔或接受任何義務或承諾公開發布任何前瞻性陳述的任何更新或修訂,以反映其預期的任何變化或任何此類陳述所依據的事件、條件或情況的任何變化。

Investor Contacts:

投資者聯繫人:

ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com

ProKidney
伊桑·霍爾達威
Ethan.Holdaway@prokidney.com

LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com

LifeSci 顧問有限公司
丹尼爾·費裏
Daniel@lifesciadvisors.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論